EP 0957941 B1 20110413 - USE OF A MELANOMA DIFFERENTIATION ASSOCIATED GENE (mda-7) FOR REVERSING A CANCEROUS PHENOTYPE
Title (en)
USE OF A MELANOMA DIFFERENTIATION ASSOCIATED GENE (mda-7) FOR REVERSING A CANCEROUS PHENOTYPE
Title (de)
VERWENDUNG DES MELANOMDIFFERENZIERUNGS ASSOZIIERTEN GENS (mda-7) ZUR UMWANDLUNG EINES KREBSPHÄNOTYPS
Title (fr)
UTILISATION D'UN GENE ASSOCIE A LA DIFFERENTIATION DES MELANOMES (mda-7) POUR INVERSER UN PHENOTYPE CANCEREUX
Publication
Application
Priority
- US 9714548 W 19970815
- US 69657396 A 19960816
Abstract (en)
[origin: EP2251040A1] This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid having the melanoma differentiation associated gene ( mda-7 ) into the cell under conditions that permit the expression of the gene so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a method for reversing the cancerous phenotype of a cancer cell by introducing the gene product of the above-described gene into the cancerous cell so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a pharmaceutical composition having an amount of a nucleic acid having the melanoma differentiation associated gene ( mda-7 ) or the gene product of a melanoma differentiation associated gene ( mda-7 ) effective to reverse the cancerous phenotype of a cancer cell and a pharmaceutically acceptable carrier.
IPC 8 full level
A61K 9/127 (2006.01); A61K 48/00 (2006.01); A61K 31/16 (2006.01); A61K 35/76 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP KR US)
A61K 31/16 (2013.01 - KR); A61K 38/1709 (2013.01 - EP US); A61K 48/00 (2013.01 - KR); A61K 48/005 (2013.01 - EP US); A61P 35/00 (2017.12 - EP); A61P 35/02 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07K 14/47 (2013.01 - EP US); A61K 48/00 (2013.01 - EP US); C12N 2710/10043 (2013.01 - EP US); Y10S 435/81 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated extension state (EPC)
AL LT LV RO SI
DOCDB simple family (publication)
EP 2251040 A1 20101117; AT E505206 T1 20110415; AU 4231997 A 19980306; AU 727735 B2 20001221; BR 9711137 A 19990817; BR PI9711137 B1 20160126; BR PI9711137 B8 20210525; CA 2263750 A1 19980219; CA 2263750 C 20090113; CN 100363057 C 20080123; CN 1166409 C 20040915; CN 1238697 A 19991215; CN 1575819 A 20050209; DE 69740175 D1 20110526; DK 0957941 T3 20110627; EP 0957941 A1 19991124; EP 0957941 A4 20010905; EP 0957941 B1 20110413; ES 2364513 T3 20110905; JP 2000516618 A 20001212; JP 2012051909 A 20120315; JP 4890666 B2 20120307; KR 100528047 B1 20051115; KR 100574049 B1 20060427; KR 20000030021 A 20000525; KR 20050054946 A 20050610; NZ 334034 A 20001027; SI 0957941 T1 20110930; US 2002091098 A1 20020711; US 2005191277 A1 20050901; US 2008057035 A1 20080306; US 2010189680 A1 20100729; US 5710137 A 19980120; US 6355622 B1 20020312; US 6855686 B2 20050215; US 7291605 B2 20071106; US 7579330 B2 20090825; WO 9806441 A1 19980219
DOCDB simple family (application)
EP 10173743 A 19970815; AT 97940569 T 19970815; AU 4231997 A 19970815; BR 9711137 A 19970815; CA 2263750 A 19970815; CN 200410054477 A 19970815; CN 97197914 A 19970815; DE 69740175 T 19970815; DK 97940569 T 19970815; EP 97940569 A 19970815; ES 97940569 T 19970815; JP 2011221094 A 20111005; JP 51010298 A 19970815; KR 19997002342 A 19990218; KR 20057004518 A 20050316; NZ 33403497 A 19970815; SI 9730796 T 19970815; US 25112499 A 19990216; US 4854305 A 20050131; US 54657309 A 20090824; US 69657396 A 19960816; US 93581607 A 20071106; US 9714548 W 19970815; US 99145201 A 20011121